Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DAKT heads into the final weeks before its December earnings with short interest climbing steadily and an activist investor quietly reducing its position, two trends that sit in tension with a stock that has managed a 4% gain over the past month.
The most notable development in the register is Alta Fox Capital Management, which holds an activist 13D position in Daktronics. Alta Fox's stake has fallen from 6.0% to 4.4% of the class, per its most recent amendment filed on August 11. That drop below a clean 5% is meaningful: a 13D filer trimming through the threshold can exit the register entirely without a further filing, so the current disclosed holding may already be stale. The disclosure caveat applies throughout: Schedule 13D/G positions are event-driven around the 5% boundary, and holders who drop below may not file again. With Alta Fox having been on the register since March 2025 and now filing six amendments, the direction of travel is clear even if the exact current level is not.
Short interest has been building in parallel with that institutional drift. Bears have added roughly 15% to their position over the past month, with short interest now running at 5.2% of the free float, a level that warrants attention even if it is not extreme. The weekly move was nearly 10%, pushing shorts to around 2.54 million shares. The borrow market tells a different story, however. Availability remains exceptionally loose at 776%, meaning there are roughly eight shares available to lend for every one already borrowed. Cost to borrow is 0.48%, firmly in low territory, and has actually eased over the past week despite the increase in short positions. There is no squeeze pressure here: shorts can build freely, and any covering would face minimal friction. Options positioning reinforces the call-heavy lean, with the put/call ratio at just 0.016, below its already-low 20-day average of 0.020, suggesting the derivatives market has little appetite for downside protection at current prices.
The Street is constructive but thinly covered. Roth Capital carried the most recent analyst action, raising its target to $29 in early July after initiating coverage at $26 in June, both with a Buy rating. The mean price target across the small analyst universe is $31, against a current price of $18.63, implying substantial return potential on paper. On valuation, the stock trades at roughly 13 times trailing earnings and 6.9 times EV/EBITDA, with the EV/EBIT factor scoring in the 81st percentile of the universe, a reasonably attractive entry on that measure. EPS momentum scores, however, rank in the 41st percentile over both 30 and 90 days, and the forward earnings growth score sits near the bottom of the range at just the 6th percentile. The picture is one of a value name where the earnings trajectory has not yet turned convincingly.
Institutional ownership data adds one more thread. BlackRock recently added 257,000 shares to bring its stake to 7.2%, the largest single holder. EARNEST Partners holds 6.4%, and Progeny 3 holds 5.7%, though those filings predate the summer. Duquesne Family Office was a notable buyer in mid-2026, adding 560,000 shares to bring its position to 2.3% of shares outstanding. The holder base is reasonably concentrated, with the top 15 institutions accounting for the majority of the float, which makes any large shift from a single name more impactful than it would be in a more widely distributed stock.
The next scheduled print is December 2, with 49 days to go. What to watch between now and then is whether Alta Fox files another amendment confirming the direction of its exit, and whether the short interest build continues to accelerate as that filing risk resolves.
See the live data behind this article on ORTEX.
Open DAKT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
